A California tech company is planning on rolling out a handful of atmospheric water generation projects near Houston. Photo via skyh2o.com

Houstonians are used to filtering their water, but few really ponder why they’re doing it.

“Most people, when they think about water stress, they think about water scarcity, like what you see happening in Northern Africa or maybe the Southern U.S.,” says Alexander von Welczeck, chairman, president and CEO of SkyH2O. “A bigger, creeping issue, particularly in the industrialized world, is water toxicity.”

Some Houston tap water contains “forever chemicals” that can be toxic, as some reports have found. In fact, says von Welczeck, water toxicity is a problem across the Gulf Coast. That’s why the California-based businessman has identified Houston as the first region to benefit from SkyH2O’s technology.

The company will break ground on its first SkyH2O Station in the first quarter of 2024 in Dickinson, strategically placed between Houston and Galveston. That will be followed by another in Angleton. Eventually, says von Welczeck, there will be eight SkyH2O stations in the greater Houston area.

Von Welczek describes a SkyH2O Station as bearing a resemblance to “a big, modern gas station, but as opposed to gas, the primary product is fresh, healthy water.” With everything from charging stations for electric vehicles to a farmers market-style set-up of sustainable food, the stations will indeed be like a futuristic gas station.

Water will be distributed both in recyclable packaging for smaller businesses and homes, and in bulk to fill water tankers for ranches and other larger customers. Von Welczeck foresees, for example, Galveston cruise ships filling up with a supply of water at that station.

But where will this fresh, clean water come from? SkyH2O uses atmospheric water generation, or AWG, systems to pull humidity from the air and turn it into potable water. The higher the humidity, the more water can be produced.

“Obviously in and around Houston, we have tremendous humidity,” von Welczeck says.

This is all done using the Maximus 4260, the latest and greatest of the company’s AWG systems. The machine is rated to produce 10,500 litres of fresh, potable water a day. It produces net zero water, meaning that it doesn’t come from any existing water resource.

What comes out initially is a semi-distilled, purified water. The next step is further filtering it and adding minerals to make the product potable for customers. Von Welczeck says that SkyH2O’s water meets the Texas Commission on Environmental Quality’s water standards.

The serial entrepreneur has been working in the climate tech space since 2002 and has a proven track record. Von Welczeck says that he sold his company, Solar Power Partners, to NRG in 2010.

“From my perspective, most everything in climate technology, whether it's clean energy, recycling, even food and water, they're all interrelated,” he says.

After opening around 20 Texas locations, von Welczeck has his sights set on covering the entire Gulf Coast. After that, he hopes to expand to Mediterranean Europe, particularly water-strapped islands. He’s even in discussions with potential clients in the Middle East. But Houston will be the first to taste SkyH2O’s potentially globe-altering water.

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from eaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in the HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”